Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO7011785
- Development stage
- Discontinued
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RO7011785 is a small molecule, selective Toll-like receptor 7 (TLR7) agonist developed by Roche for the treatment of chronic hepatitis B virus (HBV) infection. It is the active metabolite of the oral double prodrug ruzotolimod (also known as RO7020531 or RG7854). RO7011785 acts as an immunomodulator that activates TLR7, thereby stimulating the innate immune system and inducing the production of interferons and interferon-stimulated genes. This immune activation is intended to enhance the host's ability to clear HBV and achieve a functional cure. Clinical development reached Phase II, but Roche discontinued the program for chronic hepatitis B in 2021.
02
Targets
TLR7 (Toll-like receptor 7)TLR8 (Toll-like receptor 8)
Beyond the preview
Go deeper on RO7011785.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO7011785.